Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention Intravacc’s recent research, featured in the peer-reviewed journal ‘Current Opinion in Immunology’ Volume 84 (2023), explores the potential of OMV-based vaccines in mucosal immunization. OMVs, derived from Gram-negative bacteria, demonstrate promise as versatile vaccine candidates. Administered intranasally, they exhibit the capacity to carry diverse…

World Vaccine Congress Europe – Barcelona, October 16-19, 2023

We are looking forward to seeing you at “World Vaccine Congress | Europe” from 16 until 19 October in Barcelona. Our Business Development Team will be happy to see you at booth #63 and Dinja Oosterhoff, PhD, Intravacc’s Vice President R&D, will give a lecture on Thursday 19 October 10:15 about “Vaccine development using Outer Membrane Vesicle platform technology”

Intravacc publishes 2022 annual report

Intravacc publishes 2022 annual report Bilthoven, the Netherlands, 29 June 2023 – Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President Business Development and Marketing. On May 3rd the Dutch State announced the sale…